TTR and amyloidosis: The first siRNA medication, patisiran, was approved by the United States (US) Food and Drug Administration (FDA) in 2018 for the treatment of transthyretin amyloidosis by targeting the 3′UTR of the transthyretin mRNA (Setten et al., 2019).